On January 5, 2026, MetaVia, Inc. (NASDAQ:MTVA) announced positive and statistically significant results from the 8-week 48 mg cohort from the Phase 1b trial of DA-1726, the company’s dual ...

MetaVia ( (MTVA)) has provided an announcement. On January 15–16, 2026, MetaVia Inc. completed an underwritten public offering of Class A and Class B units, consisting of common stock, pre-funded ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

The underwritten public offering is comprised of an aggregate of 2,613,544 shares of common stock (or common stock equivalents), 3,920,316 Series C Warrants and 3,920,316 Series D Warrants priced at a ...

) has been revised to $100.47 / share. This is a decrease of 18.93% from the prior estimate of $123.93 dated December 18, 2025. The price target is an average of many targets provided by analysts. The ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

MetaVia ( (MTVA)) has provided an announcement. On January 5, 2026, MetaVia reported positive, statistically significant data from the extended eight-week, non-titrated 48 mg multiple ascending dose ...

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and ...

Eva Live, Inc., a technology company, develops an automated and intelligent advertiser campaign management platform in the United States. The company offers Eva Platform that enables advertisers to ...

Bíróság kötelezi az állami propagandaszervezetet, hogy hozza nyilvánosságra, mennyiért utazgattak külföldön a magyar adófizetők pénzéből. Nem titkolhatja tovább a Médiaszolgáltatás-támogató és ...